Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Eupraxia Pharmaceuticals Inc. (T.EPR) had Consolidated Net Income/Loss of -20.07M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-20.06M |
|
-- |
|
-- |
|
-- |
|
-25.07M |
|
-- |
|
-20.03M |
|
-20.02M |
|
-20.07M |
|
-20.07M |
|
|
Consolidated Net Income/Loss |
-20.07M |
-20.06M |
|
-25.07M |
|
-24.88M |
|
66.22M |
|
66.22M |
|
-0.32 |
|
-0.32 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
193.72M |
|
-- |
|
-- |
|
-- |
|
14.17M |
|
138.67M |
|
179.55M |
|
179.55M |
|
65.47M |
|
| Cash Flow Statement Financials | |
-32.18M |
|
-111.08M |
|
105.31M |
|
111.55M |
|
72.59M |
|
-38.96M |
|
7.32M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.00 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-32.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.47% |
|
-11.18% |
|
-10.36% |
|
-11.03% |
|
2.74 |
|
-0.50 |
|
-0.49 |
|